Alexion Pharmaceuticals Competitors

Amgen (NASDAQ:AMGN) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Earnings & Valuation

This table compares Amgen and Alexion Pharmaceuticals' top-line revenue, earnings per share and valuation.

Amgen has higher revenue and earnings than Alexion Pharmaceuticals. Amgen is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for Amgen and Alexion Pharmaceuticals, as provided by MarketBeat.com.

Amgen presently has a consensus price target of $256.4091, suggesting a potential upside of 15.19%. Alexion Pharmaceuticals has a consensus price target of $153.1250, suggesting a potential upside of 3.55%. Given Amgen's stronger consensus rating and higher probable upside, research analysts clearly believe Amgen is more favorable than Alexion Pharmaceuticals.

Profitability

This table compares Amgen and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Risk & Volatility

Amgen has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500.

Insider & Institutional Ownership

75.2% of Amgen shares are owned by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. 0.4% of Amgen shares are owned by company insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Amgen beats Alexion Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, dividends and profitability.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Gilead Sciences and Alexion Pharmaceuticals, as provided by MarketBeat.com.

Gilead Sciences presently has a consensus target price of $96.0370, suggesting a potential upside of 50.76%. Alexion Pharmaceuticals has a consensus target price of $153.1250, suggesting a potential upside of 3.55%. Given Gilead Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Gilead Sciences is more favorable than Alexion Pharmaceuticals.

Profitability

This table compares Gilead Sciences and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Institutional & Insider Ownership

76.4% of Gilead Sciences shares are held by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are held by institutional investors. 0.1% of Gilead Sciences shares are held by insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Gilead Sciences and Alexion Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gilead Sciences has higher revenue and earnings than Alexion Pharmaceuticals. Gilead Sciences is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Gilead Sciences has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500.

Summary

Alexion Pharmaceuticals beats Gilead Sciences on 8 of the 15 factors compared between the two stocks.

Vertex Pharmaceuticals (NASDAQ:VRTX) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, analyst recommendations and risk.

Insider and Institutional Ownership

92.2% of Vertex Pharmaceuticals shares are owned by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. 0.7% of Vertex Pharmaceuticals shares are owned by insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Vertex Pharmaceuticals and Alexion Pharmaceuticals, as provided by MarketBeat.com.

Vertex Pharmaceuticals presently has a consensus target price of $291.8462, indicating a potential upside of 40.26%. Alexion Pharmaceuticals has a consensus target price of $153.1250, indicating a potential upside of 3.55%. Given Vertex Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Vertex Pharmaceuticals is more favorable than Alexion Pharmaceuticals.

Volatility & Risk

Vertex Pharmaceuticals has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500.

Earnings and Valuation

This table compares Vertex Pharmaceuticals and Alexion Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Alexion Pharmaceuticals has higher revenue and earnings than Vertex Pharmaceuticals. Alexion Pharmaceuticals is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Vertex Pharmaceuticals and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Vertex Pharmaceuticals beats Alexion Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk and dividends.

Volatility and Risk

Regeneron Pharmaceuticals has a beta of 0.3, meaning that its stock price is 70% less volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500.

Valuation & Earnings

This table compares Regeneron Pharmaceuticals and Alexion Pharmaceuticals' gross revenue, earnings per share and valuation.

Alexion Pharmaceuticals has lower revenue, but higher earnings than Regeneron Pharmaceuticals. Alexion Pharmaceuticals is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Regeneron Pharmaceuticals and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Regeneron Pharmaceuticals and Alexion Pharmaceuticals, as reported by MarketBeat.

Regeneron Pharmaceuticals currently has a consensus price target of $625.8077, suggesting a potential upside of 40.74%. Alexion Pharmaceuticals has a consensus price target of $153.1250, suggesting a potential upside of 3.55%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Regeneron Pharmaceuticals is more favorable than Alexion Pharmaceuticals.

Institutional and Insider Ownership

85.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are owned by company insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Regeneron Pharmaceuticals beats Alexion Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Biogen (NASDAQ:BIIB) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

Profitability

This table compares Biogen and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Volatility and Risk

Biogen has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500.

Earnings & Valuation

This table compares Biogen and Alexion Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Biogen has higher revenue and earnings than Alexion Pharmaceuticals. Biogen is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for Biogen and Alexion Pharmaceuticals, as provided by MarketBeat.

Biogen presently has a consensus target price of $304.4667, indicating a potential upside of 15.36%. Alexion Pharmaceuticals has a consensus target price of $153.1250, indicating a potential upside of 3.55%. Given Biogen's higher probable upside, equities analysts clearly believe Biogen is more favorable than Alexion Pharmaceuticals.

Insider and Institutional Ownership

83.5% of Biogen shares are held by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are held by institutional investors. 0.5% of Biogen shares are held by insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Biogen beats Alexion Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

Seagen (NASDAQ:SGEN) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, dividends, valuation and profitability.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Seagen and Alexion Pharmaceuticals, as reported by MarketBeat.

Seagen currently has a consensus target price of $188.4615, suggesting a potential upside of 29.61%. Alexion Pharmaceuticals has a consensus target price of $153.1250, suggesting a potential upside of 3.55%. Given Seagen's stronger consensus rating and higher probable upside, equities research analysts plainly believe Seagen is more favorable than Alexion Pharmaceuticals.

Profitability

This table compares Seagen and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Institutional & Insider Ownership

87.2% of Seagen shares are owned by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. 31.1% of Seagen shares are owned by insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

Seagen has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500.

Valuation & Earnings

This table compares Seagen and Alexion Pharmaceuticals' revenue, earnings per share and valuation.

Alexion Pharmaceuticals has higher revenue and earnings than Seagen. Seagen is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Seagen beats Alexion Pharmaceuticals on 8 of the 14 factors compared between the two stocks.